Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Denali Therapeutics Inc.
Sponsor

Denali Therapeutics Inc.

United States 161 Oyster Point Boulevard, 94080-2042, United States

About the sponsor

Research activity includes early Alzheimer’s disease and other disorders affecting cognitive decline and brain function, with interest in central nervous system biomarkers and neuroprotective approaches.

  • Early Alzheimer’s disease
  • Central nervous system activity
  • Neurodegenerative disease

The portfolio reflects a focus on therapies intended to address disease processes within the brain and support measurable neurological outcomes.

About Specializations

Denali Therapeutics Inc. runs clinical trials in conditions such as Mucopolysaccharidosis II, Glycogen storage disease type II, Frontotemporal dementia, Parkinson's disease, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

6 clinical trials

Glycogen storage disease type II

Recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Denali Therapeutics Inc.

Frontotemporal dementia

Recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:DNL593
  • Sponsor:Denali Therapeutics Inc.

Mucopolysaccharidosis II

Recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Iduronate-2-Sulfatase Fused To A Fc Polypeptide That Binds To The Human Transferrin Receptor
  • Sponsor:Denali Therapeutics Inc.

Parkinson's disease

Not recruiting
Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine
  • Sponsor:Denali Therapeutics Inc.

Mucopolysaccharidosis II

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Idursulfase
  • Sponsor:Denali Therapeutics Inc.

Mucopolysaccharidosis II

Not recruiting
InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Iduronate-2-Sulfatase Fused To A Fc Polypeptide That Binds To The Human Transferrin Receptor
  • Sponsor:Denali Therapeutics Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.